Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer - PubMed (original) (raw)
Affiliations
- PMID: 11485087
Clinical Trial
Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer
C Prucksunand et al. Southeast Asian J Trop Med Public Health. 2001 Mar.
Abstract
The study examined patients who had symptoms indicating peptic ulcer. Forty-five patients, 24 males and 21 females, aged between 16-60 years were included in the study. Twenty-five patients, 18 males and 7 females, were endoscoped, their ulcers located in the duodenal bulb and gastric (angulus). The ulcer sizes varied between 0.5 to 1.5 cm in diameter. Capsule-filled turmeric was given orally in the dose of 2 capsules (300 mg each) five times daily, one half to an hour before meals, at 16.00 hours and at bedtime continuously. The result after 4 weeks of treatment showed that ulcers were absent in 48% or 12 cases (DU 9 and GU 3). Eighteen cases (DU 13 and GU 5) had absence of ulcer after 8 weeks of treatment. Nineteen cases (76%) (DU 14 and GU 5) did not have ulcers after 12 weeks of treatment. The rest, 20 cases were not found to have ulcers and some were not endoscoped. They appeared to have erosions, gastritis and dyspepsia. They received turmeric capsules for 4 weeks of treatment. The abdominal pain and discomfort satisfactorily subsided in the first and second week. They could take normal foods instead of soft meals. Blood chemistry and hematology of all 54 patients had no significant changes in hematological system, liver and renal functions both before and after treatment.
Similar articles
- The effectiveness of carbenoxolone in the treatment of gastro-duodenal ulcer patients.
Loginov AS, Speransky MD, Speranskaya IE, Vasilyev UV, Alecseev VF. Loginov AS, et al. Scand J Gastroenterol Suppl. 1980;65:85-91. Scand J Gastroenterol Suppl. 1980. PMID: 7010530 Clinical Trial. - NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program. National Toxicology Program. Natl Toxicol Program Tech Rep Ser. 1999 Feb;469:1-361. Natl Toxicol Program Tech Rep Ser. 1999. PMID: 12579204 - Aging and upper gastrointestinal disorders.
Pilotto A. Pilotto A. Best Pract Res Clin Gastroenterol. 2004;18 Suppl:73-81. doi: 10.1016/j.bpg.2004.06.015. Best Pract Res Clin Gastroenterol. 2004. PMID: 15588798 Review.
Cited by
- Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.
Aggarwal BB, Gupta SC, Sung B. Aggarwal BB, et al. Br J Pharmacol. 2013 Aug;169(8):1672-92. doi: 10.1111/bph.12131. Br J Pharmacol. 2013. PMID: 23425071 Free PMC article. Review. - Curcumin as a potential therapeutic candidate for Helicobacter pylori associated diseases.
Sarkar A, De R, Mukhopadhyay AK. Sarkar A, et al. World J Gastroenterol. 2016 Mar 7;22(9):2736-48. doi: 10.3748/wjg.v22.i9.2736. World J Gastroenterol. 2016. PMID: 26973412 Free PMC article. Review. - Role of curcumin in systemic and oral health: An overview.
Nagpal M, Sood S. Nagpal M, et al. J Nat Sci Biol Med. 2013 Jan;4(1):3-7. doi: 10.4103/0976-9668.107253. J Nat Sci Biol Med. 2013. PMID: 23633828 Free PMC article. - Review of Anti-Inflammatory Herbal Medicines.
Ghasemian M, Owlia S, Owlia MB. Ghasemian M, et al. Adv Pharmacol Sci. 2016;2016:9130979. doi: 10.1155/2016/9130979. Epub 2016 May 10. Adv Pharmacol Sci. 2016. PMID: 27247570 Free PMC article. Review. - Role of dietary polyphenols in the management of peptic ulcer.
Farzaei MH, Abdollahi M, Rahimi R. Farzaei MH, et al. World J Gastroenterol. 2015 Jun 7;21(21):6499-517. doi: 10.3748/wjg.v21.i21.6499. World J Gastroenterol. 2015. PMID: 26074689 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical